AVXL vs PRAX
AVXL: Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple Alzheimer's and Parkinson's trials. PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms.
Side-by-side fundamentals
| Metric | AVXL | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $2.48 | $322.40 | |
| Market cap as of 2026-07-24 | $231M | $8.9B | |
| PEG as of 2026-07-24 | n/a | -0.95 | |
| Net margin as of 2026-07-24 | n/a | -2137.5% | |
| Operating margin as of 2026-07-24 | n/a | -2340.3% | |
| ROE as of 2026-07-24 | -38.8% | -43.0% | AVXL higher |
| ROA as of 2026-07-24 | -35.0% | -40.2% | AVXL higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-24 | 1.15 | 2.81 | |
| 1-year return as of 2026-07-23 close | -77.2% | +463.3% | PRAX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.